Albert David Ltd vs Bafna Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Albert David Ltd is ₹ 800 as of 11 May 15:30 . The P/E Ratio of Albert David Ltd changed from 9.7 on March 2021 to 26.9 on March 2025 . This represents a CAGR of 22.63% over 5 yearsThe P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 years The Market Cap of Albert David Ltd changed from ₹ 215.12 crore on March 2021 to ₹ 463.25 crore on March 2025 . This represents a CAGR of 16.58% over 5 yearsThe Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 years The revenue of Albert David Ltd for the Dec '25 is ₹ 102.33 crore as compare to the Sep '25 revenue of ₹ 85.1 crore. This represent the growth of 20.25% The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 39.51 crore as compare to the Sep '25 revenue of ₹ 36.65 crore. This represent the growth of 7.8% The ebitda of Albert David Ltd for the Dec '25 is ₹ 23.22 crore as compare to the Sep '25 ebitda of ₹ 0.4 crore. This represent the growth of 5705% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 4.27 crore as compare to the Sep '25 ebitda of ₹ 5.46 crore. This represent the decline of -21.79% The net profit of Albert David Ltd changed from ₹ 18.84 crore to ₹ 15.3 crore over 7 quarters. This represents a CAGR of -11.21% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 1.84 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Albert David Ltd changed from 15.47 % on March 2021 to 16.6 % on March 2025 . This represents a CAGR of 1.42% over 5 yearsThe Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Albert David Ltd

Albert David Limited (ADL), a Unit of Kothari Group, was incorporated in 1938 at Calcutta.
The Company belongs to a renowned industrial house of Kolkata, the 'Kothari Group'.
The Company's principal business is manufacturing and trading of Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms and Bulk Drugs by way of domestic sale or export.
Apart from these, it manufactures disposable syringes and needles and a wide range of bulk drugs.
It is recognised as a large IV fluid manufacturer, both in glass and polyethylene containers. ADL has entered into a technical collaboration with Morishita Pharmaceuticals, Japan, a subsidiary of Ajinomoto -- the world leader in amino acids -- to manufacture amino acid infusions, for which it came out with a rights issue in Aug.'87.

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

FAQs for the comparison of Albert David Ltd and Bafna Pharmaceuticals Ltd

Which company has a larger market capitalization, Albert David Ltd or Bafna Pharmaceuticals Ltd?

Market cap of Albert David Ltd is 456 Cr while Market cap of Bafna Pharmaceuticals Ltd is 314 Cr

What are the key factors driving the stock performance of Albert David Ltd and Bafna Pharmaceuticals Ltd?

The stock performance of Albert David Ltd and Bafna Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Albert David Ltd and Bafna Pharmaceuticals Ltd?

As of May 12, 2026, the Albert David Ltd stock price is INR ₹800.0. On the other hand, Bafna Pharmaceuticals Ltd stock price is INR ₹133.0.

How do dividend payouts of Albert David Ltd and Bafna Pharmaceuticals Ltd compare?

To compare the dividend payouts of Albert David Ltd and Bafna Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.